$BGMD Recent News BG Medicine Inc. falls 10% in premarket

New Post Public Reply Private Reply Replies (0) Message Board

Mar 20, 2014 at 8:28 PM

$BGMD Recent News

BG Medicine Inc. falls 10% in premarket 8:58 a.m. Jan. 25, 2013 - Steve Gelsi
BG Medicine up 11% in premarket 8:57 a.m. Jan. 3, 2013 - Steve Gelsi
BG Medicine up by 16% in premarket 9:49 a.m. Dec. 14, 2012 - Steve Gelsi
BG Medicine rises 9% in premarket 10:17 a.m. Dec. 12, 2012 - Steve Gelsi
BG Medicine names BioMerieux exec as CEO 10:12 a.m. Jan. 9, 2012 - Steve Gelsi
BG Medicine names Eric Bouvier as CEO 9:38 a.m. Jan. 9, 2012 - Steve Gelsi
IPO scorecard: Pacira, Epocrates up in aftermarket 2:56 p.m. April 27, 2011 - MarketWatch.com
IPO Scorecard: Update on selected stock offerings 2:31 p.m. April 26, 2011 - MarketWatch.com

Insider Buying Is On The Rise In These 4 Rallying Stocks 6:16 p.m. Today - TheStreet.com
Why BG Medicine (BGMD) Hit a One-Year High Today (Update) 4:41 p.m. Today - TheStreet.com
BG Medicine's CEO Discusses Q4 2013 Results - Earnings Call Transcript 1:31 p.m. Today - Seeking Alpha
BG Medicine, Inc. Discusses Q4 2013 Results (Webcast) 8:25 a.m. Today - Seeking Alpha
BG Medicine up big in today's trading 1:51 p.m. March 18, 2014 - Seeking Alpha
BG Medicine meets Nasdaq requirements, shares soar 10:07 a.m. March 12, 2014 - Seeking Alpha
3 Life Science Stocks to Sell Now 3:15 a.m. Feb. 20, 2014 - InvestorPlace.com
3 Life Science Stocks to Sell Now 2:30 p.m. Jan. 30, 2014 - InvestorPlace.com
BG Medicine +24%, says clinical study shows performance of automated VIDAS 3:29 p.m. Jan. 28, 2014 - Seeking Alpha
HWAY and SulAmerica Join Forces, Shares Fall - Analyst Blog 7:30 p.m. Dec. 9, 2013 - Zacks.com
Omnicare Raises Dividend, Approves Share Repurchase - Analyst Blog 4:00 p.m. Dec. 9, 2013 - Zacks.com
Intrexon Corporation (XON) in Focus: Stock Jumps 8.6% - Tale of the Tape 10:25 a.m. Nov. 18, 2013 - Zacks.com
BG Medicine's CEO Discusses Q3 2013 Results - Earnings Call Transcript 12:03 a.m. Nov. 7, 2013 - Seeking Alpha
Healthways Partnership Expands But Stock Down - Analyst Blog 2:50 p.m. Oct. 7, 2013 - Zacks.com
CareFirst Invests in Healthways Partnership - Analyst Blog 2:50 p.m. Oct. 4, 2013 - Zacks.com
NextGxDx and athenahealth Join Forces - Analyst Blog 6:10 p.m. Oct. 1, 2013 - Zacks.com
BG Medicine Says Prelim. Decision by CMS on Galectin-3 National limitation $30.24 7:33 a.m. Sept. 30, 2013 - benzinga.com
BG Medicine - Just Be Patient 4:02 a.m. Aug. 15, 2013 - Seeking Alpha
10-Q: BG MEDICINE, INC. 4:10 p.m. Aug. 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
BG Medicine's CEO Discusses Q2 2013 Results - Earnings Call Transcript 1:35 p.m. Aug. 8, 2013 - Seeking Alpha

BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy 8:15 a.m. Today - GlobeNewswire
BG Medicine Reports 2013 Fourth Quarter and Year End Financial Results 7:50 a.m. Today - GlobeNewswire
Coverage of Top Gainers -- Research on Synta Pharma, BG Medicine, Abraxas Petroleum, and xG Technology 8:25 a.m. March 19, 2014 - PR Newswire - PRF
BG Medicine Announces Fiscal Year 2013 Financial Results Release Date and Conference Call Information 4:48 p.m. March 13, 2014 - GlobeNewswire
BG Medicine Welcomes La Jolla Pharmaceutical Company's Announcement of Positive Top-Line Results of Phase 2 Clinical Trial of Novel Pharmaceutical Compound Targeting Galectin-3 in Chronic Kidney Disease 8:46 a.m. March 12, 2014 - GlobeNewswire
BG Medicine Compliant With NASDAQ Listing Requirements 6:02 p.m. March 11, 2014 - GlobeNewswire
BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers 8:30 a.m. March 10, 2014 - GlobeNewswire
Can This Simple Test Predict Your Chances of Dying? If You Have Coronary Artery Disease, The Answer Is Yes, Say A Group of Renowned Scientists 10:00 a.m. Feb. 5, 2014 - BusinessWire - BZX
Heart Failure Study Proves Serial Testing of ST2 Can Help Improve Patient Care And Reduce Cardiovascular Events 9:59 a.m. Feb. 3, 2014 - BusinessWire - BZX
Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study 9:31 a.m. Jan. 28, 2014 - GlobeNewswire
BG Medicine to Transfer to the NASDAQ Capital Market; Obtains Requested NASDAQ Extension 9:30 a.m. Jan. 27, 2014 - GlobeNewswire
Clinical Trial Results, Partnerships, and Reimbursement Rates - Research Report on Celldex, Centene, Enanta, Novartis, and BG Medicine 9:00 a.m. Dec. 13, 2013 - PR Newswire
BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test 9:30 a.m. Dec. 10, 2013 - GlobeNewswire
Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure 9:30 a.m. Nov. 19, 2013 - GlobeNewswire
BG Medicine, Inc. Appoints Stephen P. Hall as Chief Financial Officer 9:30 a.m. Nov. 14, 2013 - GlobeNewswire
AXAS, POZN, ATRS and BGMD added to NASDAQ Active Stock Watch List at EPR 10:29 a.m. Nov. 6, 2013 - ACCESSWIRE
BG Medicine Reports 2013 Third Quarter Financial Results 8:35 a.m. Nov. 6, 2013 - GlobeNewswire
SilverStaff Clinical Laboratories to Offer BGM Galectin-3(R) Test 8:30 a.m. Nov. 6, 2013 - GlobeNewswire
BG Medicine to Announce Third Quarter 2013 Financial Results and Host Conference Call on Wednesday, November 6, 2013 8:30 a.m. Oct. 30, 2013 - GlobeNewswire
Cardiac Biomarker ST2 Helps Assess Heart Failure Risk And Identify Heart Failure Patients Likely To Benefit From Exercise 8:30 a.m. Oct. 10, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tactical Comm Market: $19.39B by 2031 Amid 8.1% CAGR

Riding the Tactical Communication Wave Alright, here’s something to chew on over your morning coffee. The tactical communication market is projected to balloon from USD 13.14 billion in 2026 to a whopping USD 19.39 billion by 2031. That’s an 8.1% CAGR if you’re keeping track—no small peanuts. So what's driving this surge? It’s all about security, modernization,...

Hexagon Seals Waygate Deal, Targets Inspection Leadership

Hexagon's Bold Move into Non-Destructive Testing Hexagon's latest play is turning heads in the measurement technology market. They've just wrapped up a strategic acquisition, snagging none other than Waygate Technologies from Baker Hughes. For those not familiar, Waygate's no small fry—this outfit's got a century-plus history in non-destructive testing (NDT) services....

Tips to Pick the Right Primary Care Provider

Deciding on Your Healthcare Anchor The quest for the perfect primary care provider isn't just routine; it's a cornerstone to your overall healthcare strategy. When Healthcare Services Expert Sheila A. Berschauer from Moses Lake Community Health lays it all out in HelloNation, she pinpoints selecting a provider as one of the mightiest decisions in your health journey. This...

Wet Noses Innovates Human-Grade Pet Food at PLMA 2026

Pet Food Revolution? Wet Noses Takes the PLMA Stage Okay, listen up, pet lovers and industry folks alike—seems like Wet Noses, that Washington-based veteran in the dog treat game, is shaking up the pet food world. After cruising through the pet aisle for almost three decades, they're making a splash at the PLMA 2026. Why should we care? Well, they’re pushing this...

Potatoes vs. Candy: Halloween's Spuddy Surprise

When Halloween rolls around, you expect rabid kids clamoring for candy corn and chocolate bars. But this year, Idaho threw a spud into the sweets machine. Idaho's Potatoes Steal the Show In an unexpected twist, the Idaho Potato Commission ran a zany experiment on Halloween: kids had to choose between their beloved Halloween candy and a genuine Idaho potato. Imagine the...

Virginia Innovation Boosts Startups and Research Growth

Virginia's Rising Innovation Ecosystem Virginia, a place you might not expect to hear much about in terms of innovation, is actually shaking things up and making waves on a national scale. Throwing their hat into the innovation arena, Virginia's landed itself a cozy #5 spot for its 'Innovation and Research Ecosystem,' according to Area Development's latest rankings. The...

Doughy Reinvents Cookie Dough with Bold New Identity

A Gourmet Transformation: Doughy's New Identity Cookie dough isn't just for sneaking off a spoon anymore, or at least that's what Doughy aims to redefine with its innovative new identity. Launched from Kelly Ramey's brainchild in her Santa Monica kitchen, Doughy's journey from a homemade recipe to a retail sensation is nothing short of remarkable. Love it or hate it, this...

PG&E's $2B Delay: A Blame Game or Real Crisis?

Just when you think the circus of energy utilities couldn't get any more outlandish, PG&E grabs the spotlight once more. Picture this: they've got the megaphone out, threatening to put the brakes on $2 billion in crucial infrastructure investments. Twenty-five thousand customers left hanging, just waiting for their lights to come on. As if that's not enough, PG&E is also...

Choosing Suit or Tuxedo: Insights for Weddings

Decoding Wedding Attire: Suit vs. Tuxedo When it comes to wedding attire, it’s not just a simple choice between a suit or tuxedo. It’s a cascading series of choices that hinge on a myriad of factors; everything from the time of day, venue, and the level of formality to personal style tweaks can sway this decision. Listen up: Men’s clothing gurus Tom Napoli and Rico...

Bright Minds in Hot Water: Investigation Shakes Investors

FDA Throws Wrench Into Bright Minds' Plans This ain't the first time a biotech company's dream has hit the skids, but Bright Minds Biosciences (NASDAQ:DRUG) found themselves in the meat grinder when the FDA threw their epilepsy trial plans under the bus. The partial clinical hold wasn't a gentle slap on the wrist, but a gut punch driven by mouse toxicity findings and...